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S. epidermidis is responsible for biofilm-related nonunions.This study compares the response to S. epidermidis-infected fractures in
rats systemically or locally injectedwith vancomycin or bonemarrowmesenchymal stem cells (BMSCs) in preventing the nonunion
establishment. The 50% of rats receiving BMSCs intravenously (s-rBMSCs) died after treatment. A higher cytokine trend was
measured in BMSCs locally injected rats (l-rBMSCs) at day 3 and in vancomycin systemically injected rats (l-VANC) at day 7
compared to the other groups. At day 14, the highest cytokine values were measured in l-VANC and in l-rBMSCs for IL-10. 𝜇CT
showed a good bony bridging in s-VANC and excellent both in l-VANC and in l-rBMSCs. The bacterial growth was lower in s-
VANC and l-VANC than in l-rBMSCs. Histology demonstrated the presence of new woven bone in s-VANC and a more mature
bony bridging was found in l-VANC.The l-rBMSCs showed a poor bony bridging of fibrovascular tissue. Our results could suggest
the synergic use of systemic and local injection of vancomycin as an effective treatment to prevent septic nonunions. This study
cannot sustain the systemic injection of BMSCs due to high risks, while a deeper insight into local BMSCs immunomodulatory
effects is mandatory before developing cell therapies in clinics.
1. Introduction
Open fractures are notorious to be at high risk of bacterial
contaminations, mainly supported by the osteosynthesis
devices that induce the biofilm development and a delayed
bone healing [1]. S. epidermidis is one of the most involved
pathogens in bone infections and nonunions [2] creating
a protective niche from antimicrobial treatments [3]. At
present, the standard therapy for orthopaedic infections
implicates the systemic administration of antibiotics [4].
However, the long-term use of antibiotics, insufficient to
reach bacteria within the biofilm matrix, generates a mul-
tidrug resistance leading to methicillin-resistant S. epider-
midis (MRSE) [5]. Moreover, the antibiotic prophylaxis could
be inadequate in case of fractures associated with vascular
injuries, which reduce the local drug concentration. Hence,
alternative prophylaxis strategies need to be assessed not only
to prevent bacterial infections but also to support the bone
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repair. Many antimicrobial agents have been incorporated
into biomaterials to be locally delivered [6]. Specifically,
a novel bioresorbable hydrogel was in vitro and in vivo
validated as an orthopaedic implant coating and antibiotic
slow-releasing delivery to impair the bacterial coloniza-
tion through an antimicrobial competitive inhibition [7–9].
Nowadays, cell therapies have also been proposed to promote
the bone repair [10]. Mesenchymal stem cells (MSCs) are
claimed to be one of the most frequently used cell types
thanks to their high proliferative ability and easy accessibility.
MSCs have unique immunologic features that support their
viability and proliferation in nonself environments [11]. The
use of allogeneic MSCs may drastically reduce the waiting
time to obtain a relevant cell amount for clinical use [12],
as supported by orthopaedic clinical trials (ClinicalTrial.gov
#NCT02307435 and #NCT01586312). Furthermore, MSCs
ability to restrain bacterial infections has been hypothesized
having both proangiogenic and immunomodulatory charac-
teristics that promote the release of mediators (cytokines and
chemokines) [13, 14]. In a recent study, we provided evidence
of dose-dependent MRSE-induced nonunions in rats [15],
demonstrating that subclinical orthopaedic infections are
diagnosed with a significant delay. Typically, in clinics, the
C reactive protein remains the most used biomarker of
infection, despite a scarce sensitivity and specificity [16]. To
supportmedical treatments for infections, identifying reliable
predictive markers is urgency. Cytokines play an important
role during the host response to infections inflammation and
tissue repair by recruiting the cell mediated immunity, before
any clinical appearance [17]. Importantly, the inflammation
associated with fractures induces a precocious cytokine
release that is essential during the early stage of bone healing
[18]. However, a prolonged release of inflammatory cytokines
fails to stimulate the osteogenic differentiation of resident
MSCs recruited on the fracture site leading to an impaired
healing [18], and the presence of bacteria highly influences
the inflammatory cytokines and bone healing.
In the present study, we compare the host response to
MRSE-related infections of femoral fractures in rats treated
with cell therapies, conventional systemic antibiotic prophy-
laxis, and antibacterial-coated implant devices. We hypothe-
size that transplanted MSCs in a nonunion rat model could
have benefits on bone healing and prevention of septic
nonunion development thanks to MSC immunomodula-
tory effects. Moreover, we hypothesize a role of circulating
cytokines in the MRSE-related infections presuming a differ-
ent activity, according to the received treatments.
2. Materials and Methods
2.1. Study Design and Procedures. This study on animals was
approved by the Mario Negri Institute for Pharmacologi-
cal Research (IRFMN) Animal Care and Use Committee
(IACUC) (Permit number 06/2014-PR).The IRFMN adheres
to the principles set out in the following laws, regulations,
and policies governing the care and use of laboratory animals:
Italian Governing Law (D.lgs 26/2014; Authorization number
19/2008-A issued March 6, 2008, by Ministry of Health);
Mario Negri Institutional Regulations and Policies providing
internal authorization for persons conducting animal exper-
iments (Quality Management System Certificate—UNI EN
ISO 9001:2008—Reg. number 6121); the NIH Guide for
the Care and Use of Laboratory Animals (2011 edition);
and EU directives and guidelines (EEC Council Directive
2010/63/UE).The Statement of Compliance (Assurance) with
the Public Health Service (PHS) Policy on Human Care
and Use of Laboratory Animals has been recently reviewed
(9/9/2014) and will expire on September 30, 2019 (Animal
Welfare Assurance #A5023-01).
Thirty 12-week-old male Wistar rats (body weight 373.56
± 24.82 g) (Harlan Laboratories SRL) were used in this study.
Briefly, rats were maintained under general anesthesia and
received a preoperative intramuscular single injection of
cefazolin (30mg/kg, Cefamezin, Teva) and a subcutaneous
treatment with carprofen (5mg/kg, Rimadyl, Pfizer).The rats
were osteotomized on the right femur and the fracture was
synthesized with stainless steel plate and bicortical screws
(all fromZimmer, Germany). All animals were injected into
the femoral defect with an inoculum of 1 × 105 CFU/30 𝜇L
of MRSE strain #GOI1153754-03-14, as validated and widely
described in our previous study [15]. Briefly, to prepare the
inoculum, a colony of the MRSE strain was cultured into
Brain Heart Infusion Broth (BioMe´rieux) and incubated at
37∘C for 16 hours. The bacterial pellet was suspended in
sterile saline to obtain a 10McFarland turbidity equal to about
3 × 109 CFU/mL; then the bacterial suspension was diluted
with sterile saline solution to obtain a bacterial load of 1 ×
105 CFU/30 𝜇L.The bacterial inocula were confirmed by agar
plate counting procedures and stored at 4∘C until use.
After the bacterial inoculum, the muscular planes were
closed with Polysorb 4/0 and the skin with Monosof 4/0
(Covidien). The rats were randomly divided into five groups
(𝑛 = 6 each group): the positive control group (PC) did
not receive any therapeutic treatment (Figure 1(a)); the sys-
temically treated groups received intravenously vancomycin
(15mg/kg, Hikma) (s-VANC) or allogeneic rat bone marrow
MSCs (s-rBMSCs) immediately after surgery; the locally
treated groups received a local injection of rBMSCs (l-
rBMSCs) (Figure 1(b)) 24 hours after surgery or a local lay-
ering of a vancomycin-enriched hydrogel (l-VANC) (Figures
1(c) and 1(d)) during surgery.
Atipamezole (1mg/kg, Antisedan, Pfizer) was adminis-
tered subcutaneously to recover rats from general anesthesia.
The animals were monitored daily for general status and
welfare, clinical signs of infection, lameness, weight bearing,
swelling, local hyperemia, wound healing, serous exudate,
hematoma, pain, and suffering. The pain was controlled with
buprenorphine (0.1mg/kg SC, Temgesic, Schering Plough,
Italy) immediately after surgery.
Three animals of the s-rBMSCs group died within 6–10
hours after surgery for respiratory complications.Their lungs
and hearts were explanted and histologically analyzed. From
here on, the investigations regarding the s-rBMSCs group
were performed on the remaining three animals.
Overall, the animals were monitored for body weight
changes, neutrophil counts, and circulating cytokines during
the follow-up period. After 6 weeks, rats were euthanized
by CO
2
and 𝜇CT scans; microbiological and histological
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Figure 1: Treatments in the experimental groups. (a) All animals received MRSE locally. The picture represents the injection of the bacterial
suspension within the site of the fracture. (b) Representative picture of the local treatment with rBMSCs in the site of the fracture 24 h after
surgery.The picture represents the transcutaneous injection of rBMSCs after disinfection within the site of the fracture. (c)The l-VANC group
received a vancomycin-enriched hydrogel locally layered on the plate surface before the fracture stabilization and (d) within the site of the
osteosynthesis after the plate fixation. The pictures represent the distribution of 250 𝜇L of the vancomycin-enriched hydrogel on the bottom
(c) and top side of the plate (d).
analyses were performed to assess the bone healing and
infection.
2.2. Culture and Preparation of Rat BMSCs. Allogeneic Wis-
tar rBMSCs (Oricell, Cyagen Biosciences, Cat. number
RAWMX-01001, passage 2) were used. Cells were expanded
in medium composed of 4.5 g/L glucose Dulbecco’s Modified
Eagle’s Medium, 100U/mL penicillin-streptomycin, 2mM
L-glutamine, 1% sodium pyruvate, 1% HEPES (all from
Gibco), and 10% fetal bovine serum (Hyclone). At passage 5,
undifferentiated rBMSCs were differently injected in the rats
at concentration of 2 × 106 cells/kg.
2.3. Antimicrobial Coating Preparation. A resorbable hydro-
gel calledDAC (Defensive Antibacterial Coating, Novagenit
Srl) was enriched with vancomycin at 5% (v/w), accord-
ing to manufacturer’s guidelines and others [8], and then
distributed on plates and screws during the osteosynthesis
of the l-VANC group. Briefly, to prepare the vancomycin-
enriched hydrogel, 500mg of vancomycin was diluted in
10mL of sterile water, and then 5mL of this suspension was
used to solubilize the hydrogel, thus obtaining an enriched
hydrogel containing 50mg/mL of vancomycin. In the l-
VANC group, plates and screws implanted were coated with
250 𝜇L of enriched hydrogel, thus delivering locally 35mg/kg
of vancomycin.
2.4. Body Weight and Blood Analyses. The rat body weight
was measured before surgery and weekly until the day of
explantation (day 42) and reported as relative b.w. increase
on the baseline (day of surgery). On days 0, 14, and 42 (𝑛 = 6
per group; 𝑛 = 3 s-rBMSCs), venous blood was harvested
from the tail vein under general anesthesia and then trans-
ferred into K
2
EDTA tubes (Microtainer MAP, Becton Dick-
inson) to determine the neutrophil count. On days 3, 7, and
14 after surgery, plasma was obtained by centrifuging the
samples (𝑛 = 4 per group; 𝑛 = 3 s-rBMSCs) at 1200×g for
10min at RT and stored at −80∘C until use for the cytokine
analysis (IL-1𝛼/𝛽, IL-6, IL-10, TNF-𝛼, and IFN-𝛾) by means
of the Luminex assay kit (Bio-Plex Pro Rat Cytokine
Assay, Bio-Rad) according to themanufacturer’s instructions.
Measurement was performed in duplicate by using a Bio-Plex
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200 system based on the Luminex xMAP technology (Bio-
Rad, Hercules). Cytokine levels are reported as pg/mL.
2.5. Micro-CT Imaging. The qualitative and quantitative 𝜇CT
analyses on femurs were performed with an Explore Locus
𝜇CT scanner (GE Healthcare), as previously described else-
where [15].
Bony bridging percentage of >75%, 50–75%, or <75% of
the fracture gap was evaluated and scored. The bone volume
(BV, mm3) and tissue mineral density (TMD, mg/cc) were
calculated within the volume of interest, as described by
others [19]. Data were reported as fold increase of the treated
groups on the PC group.
2.6. Microbiological Analysis. After 42 days, bacteria were
recovered from explanted femurs (𝑛 = 6 per group;
𝑛 = 3 s-rBMSCs) by treating samples with dithiothreitol
to dislodge bacteria from the biofilm and analyzed as previ-
ously described [15, 20]. Data were reported as Log (CFU/g)
explant.
2.7. Histological Analysis. Femurs (𝑛 = 6 per group; 𝑛 = 3 s-
rBMSCs) were fixed in 10% formalin, decalcified in Osteodec
(Bio-Optica), embedded, and cut into 5 𝜇m sections. Haema-
toxylin and eosin (H&E) staining was performed to assess
morphology, fracture healing, and signs of osteomyelitis.The
Gram-positive stainingwas evaluated for presence or absence
of bacteria. Olympus IX71 light microscope and Olympus
XC10 camera (Japan) were used to obtain images.
2.8. Statistical Analysis. After verifying the normal distribu-
tion of data with the Shapiro-Wilk test, comparisons among
groups and time points were analyzed with two-way analysis
of variance (ANOVA) and comparisons among groups were
analyzed with one-way ANOVA (GraphPad Prism v5.00
Software) and then coupled with Bonferroni’s post hoc test.
All data are expressed as means ± standard error (SE). Values
of 𝑝 < 0.05 were considered statistically significant.
3. Results
3.1. Clinical Examination. The histological analysis of the
organs of the s-rBMSCs treated rats did not show any cardiac
alteration but assessed the presence of acute hyperemia
associated withmultifocal alveolar edema and hemorrhage in
the lungs (Figure 2). Despite emboli within pulmonary arter-
ies were not evident, the interlobular septa were markedly
inflated with fluid and diffuse congestion (Figure 2, asterisk),
presence of macrophages and polymorphonucleated cells
within the parenchyma indicating a severe inflammatory
reaction.
During the follow-up period, no other animals of any
group died or presented peri-implant inflammation. From
days 3 to 7, three PC rats showed a partial load bearing on
the operated limb without any clinical evidence of infection.
3.2. Body Weight and Blood Analyses. The relative b.w.
increase on the baseline was represented in Figure 3(a). At
day 7, a b.w. loss was recorded in all groups. At day 14, l-
rBMSCs and l-VANC showed a b.w. decrease and a slower b.w.
recovery throughout the experimental follow-up compared
to the other treated groups. Differently, s-VANC depicted a
significant b.w. increase compared to l-VANC, l-rBMSCs, and
PC over time. In Figure 3(b), the neutrophil count is reported
as number of neutrophils ×103/𝜇L compared to the baseline
(day 0). After 14 days, PC showed a significant neutrophil
increase compared to the basal values and to l-VANC.
After 42 days, the neutrophil count almost normalized in
all groupswithout any significant differences compared to the
basal values and among the experimental groups.
3.3. Pro- and Anti-Inflammatory Cytokines. Plasma levels
of proinflammatory (IL-1𝛼/𝛽, TNF-𝛼, and IFN-𝛾), anti-
inflammatory (IL-10), and regulatory (IL-6) cytokines were
assessed at days 3, 7, and 14 (Figure 4). In most of the
groups, all cytokines showed the same changes with time.
Overall, at day 3, PC and l-rBMSCs had a higher cytokine
trend with respect to the other groups. At day 7, PC and s-
VANC showed a higher cytokine trend compared to the other
groups. Similarly, this trendwas found for IL-1𝛽 in s-rBMSCs,
for IL-10 in l-rBMSCs, and for IFN-𝛾 in l-VANC. At day 14,
the highest cytokine values weremeasured in PC and l-VANC
and just for IL-10 in the l-rBMSCs group.
Particularly, PC had a higher trend for all the analyzed
cytokines compared to the other groups at day 3 andpeaked at
7 days after injection.Moreover, PC demonstrated the highest
cytokine activity compared to the treated groups. Mainly at
day 7, PC had increased values of the acute phase cytokines
(IL-1𝛼/𝛽 and TNF-𝛼) with significant differences compared
to l-VANC, s-rBMSCs, and l-rBMSCs. This trend was found
also on day 3 for TNF-𝛼 in the PC group. Moreover, s-VANC
showed a higher trend compared to l-VANC. Differently,
the anti-inflammatory cytokines (IL-10) and the late phase
(IFN-𝛾 and IL-6) did not show a significant difference in
PC compared to all the treated groups. At day 3, l-rBMSCs
showed higher values for IL-1𝛼/𝛽, TNF-𝛼, and IFN-𝛾 with
respect to s-VANC and l-VANC. At day 14, l-VANC showed
a higher trend with respect to the other groups in all the
analyzed cytokines, with a significant difference for TNF-𝛼
and IL-6 with respect to s-VANC.
3.4. Micro-CT Imaging Diagnosis. The 𝜇CT qualitative anal-
ysis depicted a variable percentage of bony bridging in the
experimental groups (Table 1).
In particular, s-VANC displayed a good to total bony
bridging in the 67% and 33% of the cases, respectively. In this
group, no bone osteolysis was detected and a mild cortical
reaction was visible near to the fracture site (Figure 5(a),
white arrows), confirmed by the 3D reconstruction (Fig-
ure 5(b)). Overall, l-VANC (Figures 5(c) and 5(d)), s-rBMSCs
(Figures 5(e) and 5(f)), and l-rBMSCs (Figures 5(g) and 5(h))
showed a higher percentage of fracture healing characterized
by a well-structured bone callus and mineralized cortices in
most of the cases (50 to 100%), and a good osseointegration
of the screws was present in all cases. A medullary reaction
was detected in l-rBMSCs (Figure 5(g)) together with a mild
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Figure 2: Representative histological panel of the rat lungs reporting the effects of the acute intravenous administration of allogeneic BMSCs
in the s-rBMSCs group.The lung sections are stained with haematoxylin and eosin. (a, b) Presence of acute and diffuse hyperemia within the
lung parenchyma. (c) Presence of multifocal alveolar edema (∗). (a) scale bar 1000 𝜇m; (b) scale bar 200 𝜇m; (c) scale bar 50 𝜇m.
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Figure 3: Clinical data. (a)The histogram shows the relative changes in body weight in the experimental groups over time. (b)The histogram
shows the systemic neutrophil count in the experimental groups at days 14 and 42 after surgery. Comparisons between groups and time points
were analyzed with two-way ANOVA and Bonferroni’s post hoc test. Statistical significance was 𝑝 < 0.05 (∗), 𝑝 < 0.01 (A, ∗∗), and 𝑝 < 0.001
(#); 𝑛 = 6, 𝑛 = 3 s-rBMSCs.
Table 1: Percentage of bony bridging of the fracture site.
Bony bridging
< 75%
nonunion
fracture
Bony bridging
50–75%
partial fracture
healing
Bony bridging >
75%
fracture healing
PC 83% (5/6) 17% (1/6) n.d. (0/6)
s-VANC n.d. (0/6) 67% (4/6) 33% (2/6)
l-VANC 33% (2/6) 17% (1/6) 50% (3/6)
s-rBMSCs n.d. (0/3) n.d. (0/3) 100% (3/3)
l-rBMSCs 33% (2/6) 17% (1/6) 50% (3/6)
n.d.: nondetectable.
cortical reaction identified in the 3D reconstruction (Fig-
ure 5(h)). Otherwise, the PC group confirmed data obtained
in our previous study [15], depicting an evident nonunion
associatedwith a femoral diaphysis deformity and dislocation
of the bone stumps due to the loss of implant stability and
severe osteolysis (Figures 5(i) and 5(j)). The osteomyelitis
grading score for this group showed significant difference
with respect to all the treated groups, while no significant dif-
ferences were found between the treated groups (Figure 5(k)).
BV and TMD were reported as fold increase with respect
to the PC group in Figures 6(a) and 6(b). No significant
differences were found for BV between the treated groups;
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Figure 4: Cytokine analysis.The histograms show the cytokine values of the experimental groups at 3, 7, and 14 days after surgery and bacterial
injection. Comparisons between groups and time points were analyzed with two-way ANOVA and Bonferroni’s post hoc test. Statistical
significance was 𝑝 < 0.05 (∗), 𝑝 < 0.01 (∗∗), and 𝑝 < 0.001 (∗∗∗); 𝑛 = 4, 𝑛 = 3 s-rBMSCs.
differently, the fold increase of TMDwas higher in s-rBMSCs
with respect to both l-VANC and l-rBMSCs.
3.5. Microbiological Analysis. The microbiological analysis
reported in Figure 7 detected a significant higher bacterial
growth between PC and both s-VANC and l-VANC. More-
over, l-VANC showed a lower bacterial growthwith respect to
l-rBMSCs. The limit of detection was set at 0.18 Log (CFU/g)
explant.
3.6. Histological Analysis. The H&E staining confirmed the
results obtained by 𝜇CT in terms of percentage of fracture
healing and absence of osteomyelitis in s-VANC, l-VANC, and
s-rBMSCs (Figure 8). Specifically, in s-VANC, the fractures
appeared repaired by a great amount of newly bone deposi-
tion in a remodeling phase (woven bone), coupledwith amild
cortical thickening and periosteal reaction. Both in l-VANC
and s-rBMSCs, a complete closure of the fracture was found
and the new bone appeared more mature and lamellar than
in s-VANC. The l-VANC group showed uniformly enlarged
cortices with areas of bone remodeling. In l-rBMSCs, 17% of
samples presented only a partial bony bridging characterized
by a great deposition of fibrovascular tissue invading the
fracture site and surrounding the screws disseminated with
giant cells. In all the aforementioned groups, a moderate
presence of polymorphonucleated cells was found within the
medullary canal. The PC group showed disorganized bone
architecture, a lot of fibrovascular tissues, and nonunion
establishment. The periosteal reaction, myeloid hyperplasia,
and presence of intact and fragmented polymorphonuclear
cells in the granulation tissue associated with several vascular
vessels represented signs of osteomyelitis.
The Gram staining confirmed the quantitative data
obtained from the microbiological tests (Figure 9). Indeed,
in all groups, the presence of cocci was detected. In particu-
lar, s-VANC, s-rBMSCs, l-rBMSCs, and PC showed several
cocci assembled in clusters and diffuse within the bone
and periosteal tissue. Differently, l-VANC showed scarce
dispersed cocci within areas of new bone formation in the
fracture site.
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Figure 5: Qualitative 𝜇CT imaging, isosurface, and semiquantitative osteomyelitis score. The representative panel shows 𝜇CT images on the
day of explantation. (a, c, e, g, i) Sagittal, coronal, and axial planes. (b, d, f, h, j) 3D isosurface reconstruction is presented for the s-VANC, s-
rBMSCs, l-VANC, l-rBMSCs, and PC groups. Symbols indicate cortical reaction (white arrows);medullary reaction (yellow arrow); and loss of
cortical wall and osteolysis (asterisks). (k) Osteomyelitis grading score based on Odekerken’s scale is reported in the histogram. Comparisons
among groups were analyzed with one-way ANOVA corrected with Bonferroni’s post hoc test. Statistical significance was 𝑝 < 0.05 (∗) and
𝑝 < 0.001 (∗∗∗); 𝑛 = 6, 𝑛 = 3 s-rBMSCs.
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Figure 7: Microbiological detection of bacterial growth on the
explanted specimens. The limit of detection (L.o.D.) was set at 0.18
Log (CFU/g)/explant. Comparisons among groups were analyzed
with one-way ANOVA corrected with Bonferroni’s post hoc test.
Statistical significance was 𝑝 < 0.05 (∗), 𝑝 < 0.01 (∗∗), and 𝑝 <
0.001 (∗∗∗); 𝑛 = 6, 𝑛 = 3 s-rBMSCs.
4. Discussion
This comparative study analyzes for the first time the effi-
cacy of systemic antimicrobial prophylaxis and antibacterial
coating of orthopaedic implants and cell therapy on MRSE-
induced nonunions in rats. We hypothesized that the use of
allogeneicMSCs could improve the host response to bacterial
infections based on the potential immunomodulatory effects
directly on the injured site [21].
In our study, the amount of systemically or locally injec-
ted rBMSCs was concordant with the dosage used in the
literature for cardiovascular or autoimmune diseases [22, 23],
as demonstrated to reach damaged sites. However, in our
series, we had a 50% of animal death when intravenously
injected with rBMSCs (s-rBMSCs). The histological analysis
supported the “pulmonary first-pass theory,” in which a
scarce cellular delivery has been demonstrated due to the lung
filter in either animals or humans [24–27].This phenomenon
should be related to the cell adhesion, the activation of the
coagulation pathway, and anaphylactic reactions promoted
by the allogeneic MSCs causing pulmonary embolisms [23,
28]. Hereon, it is worth taking into account that the data
obtained in the s-rBMSCs group considered only three ani-
mals and they cannot offer a good sample sizing to properly
sustain our results, representing a limit of our study.
The pathogenesis of bone infections after severe fractures
is strictly related to the biofilm formation, making difficult
both the diagnosis and the efficacy of treatments. Thus,
identifying specific biomarkers would be crucial to early
detection of the grade of infection. In our study, we evaluated
cytokines produced in both the acute (IL-1𝛼/𝛽 and TNF-
𝛼) and the chronic phases (IFN-𝛾, IL-10, and IL-6) of
inflammation/infection and involved in the bone remodeling
(IL-6). Specifically, IL-6 has a bivalent function depending on
the mode of expression: persistently high (even moderate)
levels are associated with a proinflammatory activity whilst
a peaking behavior is associated with an anti-inflammatory
proregenerative effect [29]. However, the inability to discrim-
inate between changes from postsurgical trauma and MRSE-
induced infection could represent a limitation. Overall, we
demonstrated significant differences among groups after 7
days of infection. Due to the staphylococcal toxin release,
TNF-𝛼 showed difference already at day 3, being the primary
involved cytokine [30]. Moreover, we demonstrated the
simultaneous activation of both pro- and anti-inflammatory
cytokines.
At day 7, higher IL-1𝛼/𝛽 and TNF-𝛼 values in the PC
group with respect to the others may have been in response
to inflammatory stimuli because of bacterial growth and
biofilm formation.This correlates with the greater neutrophil
count at 14 days, when neutrophils mediate the recruitment
of macrophages maintaining high levels of cytokines [31, 32].
Similarly, on day 7, s-VANC showed increased IL-1𝛼/𝛽 and
TNF-𝛼 values compared to the other treated groups, relating
to a reduced efficacy of one-shot injected vancomycin. It is
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Figure 8: Histological analysis (H&E) at the day of explantation. The representative panel shows H&E staining of the femurs in all the
experimental groups. The panels depict an overview of the samples, scale bar 1mm. WB: woven bone; LB: lamellar bone; PR: periosteal
reaction; FV: fibrovascular tissue; MH: myeloid hyperplasia; vascular infiltrates (black arrow); alteration of cortical bone (green arrow). For
the l-rBMSCs group, (a) a specific area containing fibrovascular tissue and polymorphonucleated cells is reported in the big black box (scale
bar 200 𝜇m) and (b) the presence of giant cells in the small black box (scale bar 100 𝜇m) is reported. For the PC group, (c) a specific area with
fibrovascular tissue is reported in the big red box (scale bar 200 𝜇m) and (d) the myeloid hyperplasia is shown in the small red box (scale bar
200 𝜇m).
known that vancomycin acts both directly against bacteria
and as an immunomodulatory drug, inhibiting the cytokine
production during the early stages [33], as we also demon-
strated at day 3.
On day 14, higher cytokine levels in l-VANC compared to
the other groups could be caused by the local inflammatory
response through the activation of macrophages that inter-
vene against the material debris and could affect the bone
repair, as also demonstrated by others [34]. Moreover, we
detected high levels of IL-6 in l-VANC after 14 days, predict-
ing a lower systemic efficacy of this treatment with respect
to the conventional prophylaxis therapy [35]. However, IL-6
is involved in the modulation of bone cells during repair by
suppressing the differentiation of the osteoclast progenitors
[36, 37]. The increase of IL-1𝛽, IFN-𝛾, and TNF-𝛼 found
in l-rBMSCs at day 3 could be related to the antiapoptotic
activity of MSCs on neutrophils in the microenvironment
of a damaged and infected tissue [38, 39]. These data were
also confirmed by the neutrophil analysis andwere consistent
with those described by Seebach et al. [13]. Furthermore,
these inflammatory cytokines can stimulate the MSCs to
release a large amount of growth factors promoting the
tissue repair [40]. Again, we detected an upregulation of
IL-10 in l-rBMSCs at days 7 and 14. Specifically, IL-10,
produced by the macrophages present in the histological
sections of l-rBMSCs, has a regulatory role in immunological
and inflammatory responses by decreasing the production
of proinflammatory cytokines, as demonstrated here and
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Figure 9: Gram staining of the femurs at the day of explantation. The representative panel shows the Gram staining of the femurs in all the
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by others [41]. Indeed, the interaction between MSCs and
macrophages secretes prostaglandin E2 that reprograms the
macrophages to release IL-10 [39]. The increase of IL-10
in l-rBMSCs suggests that MSCs can modulate the host
immune response to infection. Otherwise, a similar behavior
for the s-rBMSCs group could not be supported by this study
because of the small number of survived animals. Thus, the
clinical results in the s-rBMSCs group (𝜇CT and histology)
cannot be considered representative for the efficacy of this
treatment. Concerning the other groups, the semiquantitative
Odekerken’s score for osteomyelitis was supported by the BV
and TMDmeasurements, in which no significant differences
were found among s-VANC, l-VANC, and l-BMSCs groups.
The 𝜇CT and histological analyses of the PC group
generated results consistent with those of our previous study
[15], demonstrating the development of septic nonunions.
The same analyses highlighted a worse osteomyelitis score
in the l-rBMSCs group compared to the antibiotic treated
groups, as also supported by Seebach et al. [13]. This is
potentially due to the release of cellular proteases by dead
MSCs that could negatively act on bone repair and support
the bacterial colonization.This was also demonstrated by the
microbiological tests measuring a greater bacterial growth in
l-rBMSCs compared to the antibiotic treated groups.
Overall, our study demonstrated a good response in terms
of bone healing and absence of osteomyelitis in s-VANC and
l-VANC.
5. Conclusions
Through our results, we could suggest the synergic use of
systemically injected vancomycin and its local delivery as
an effective treatment to prevent the bacterial spread in
orthopaedic infections. The hydrogel, used in this study,
could also ameliorate the bone repair towards a more mature
bone thanks to its capability in stimulating bone specific
cytokine (IL-6). Otherwise, our study cannot definitely sus-
tain the use of cell therapy for this purpose. Indeed, the
intravenous injection of MSCs should be considered a highly
risky treatment with a high rate of mortality. However, based
on our preliminary results on the local injection of MSCs,
a deeper insight into their immunomodulatory mechanisms
in a large experimental design should be helpful to develop
novel strategies for the clinical use of MSCs.
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